An updated risk score from New York City-based Mount Sinai researchers can help predict possible contrast-associated acute kidney injury among patients undergoing percutaneous coronary intervention, according to a Nov. 15 press release.
"Simple measures can be taken around the time of procedure when a patient is identified to be at high risk of [contrast-associated acute kidney injury] CA-AKI, and we hope this new score is widely adopted to enhance the care of patients and improve outcomes," said Roxana Mehran, MD, principal researcher and professor of Medicine, and Population Health Science and Policy, and director of Interventional Cardiovascular Research and Clinical Trials at the Icahn School of Medicine at Mount Sinai.
The risk score, called "The Mehran-2 CA-AKI Risk Score," was presented Nov. 15 at the American Heart Association Scientific Sessions 2021 with simultaneous publication in The Lancet.
Researchers used records of 30,000 patients, all of which had creatinine tests, who underwent the procedure at The Mount Sinai Hospital between 2012 and 2020 to create a predictor model based on baseline risk factors.
The updates take into account changes in practice surrounding percutaneous coronary intervention, including more advanced imaging techniques requiring less toxic contrast agents and improved stents.